Please Wait...

Margaret Ziola

Translation skills

Main profile

Margaret Ziola, MD
Medical Director, Cardiology and Neurovascular

In her position as Medical Director, Cardiology and Neurovascular at Synarc, she is responsible for the scientific oversight of all cardiovascular projects including coordination and collaboration with key opinion leaders and expert readers as well as our Sponsor's scientific counterparts. Dr. Ziola participates in clinical trial protocol design and data interpretation and regulatory strategy planning. She oversees the quality of Synarc's cardiology and neurovascular reading services and explores new applications of imaging to clinical trial research.

Dr. Ziola has more than twenty years of cardiovascular experience in support of pharmaceutical research and development programs. Her expertise includes clinical analysis, interpretation, and reporting of cardiac safety data for over 100 clinical trials in various therapeutic indications, including cardiovascular, infectious disease, oncology, CNS, gastroenterology, and endocrinology.

Dr. Ziola holds her medical degree from the Nicolaus Copernicus Jagiellonian University Medical School in Krakow, Poland. She has participated in expert meetings, given invited lectures and co-authored several scientific articles.

Prior to joining Synarc, Dr. Ziola worked at ARYx Therapeutics leading global cardiovascular clinical trials design, conduct and monitoring. Earlier in her career, she served as Director of Cardiovascular Clinical Services position at Gentiae Clinical Research, a cardiovascular core lab she helped establish, supporting central reading of cardiac imaging and electrocardiography. Prior to that she was affiliated with the groundbreaking Ischemia Research and Education Foundation.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @MdFacep: FDA approvals: Merck's Keytruda wins FDA approval as combination therapy for kidney cancer. BIG! https://t.co/LgCzL1mvaF @Reu…
Bioclinica (11 hours ago)
RT @FDA_Drug_Info: National Prescription Drug Take Back Day is April 27, 2019 from 10:00 AM to 2:00 PM. Learn how to dispose of unused and…
Bioclinica (11 hours ago)
RT @iofbonehealth: #Osteoporosis Int: Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international…
Bioclinica (11 hours ago)
RT @HINJ_ORG: New Jersey's biopharmaceutical industry: CIANJ has assembled a panel of industry leaders @Celgene, @Bayer & @PhRMA to discuss…
Bioclinica (11 hours ago)
RT @PhRMA: Last year, the top 15 largest biopharmaceutical companies spent more than $100 billion on R&D, according to @IQVIA_global. More…
Bioclinica (11 hours ago)
RT @SCDM_DataDriven: Registrations for the SCDM 2019 Annual Conference are now open!! #SCDM2019 Register now for the biggest event in the…
Bioclinica (11 hours ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box